Ittetsu Takeda holds the title of Head Coach, but without any volleyball experience, it's a title in name only. Knowing this, and seeing the untapped potential in the current roster of players ...

Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Global biopharmaceutical company Takeda has launched an innovation capability centre (ICC) in Bengaluru, India, joining existing facilities in Slovakia and Mexico. The Bengaluru ICC will focus on ...

Takeda Pharmaceutical Company ( (TAK) ) has shared an update. Takeda Pharmaceutical Company has submitted an extraordinary report detailing its decision to dissolve its specified subsidiary, Shire ...

As Hinata and Kageyama stew in their sorrows, teacher Ittetsu Takeda comes to not only lift their spirits but confront the mindset that could keep them from future successes. Takeda started with ...

His gruff personality balances out faculty advisor Ittetsu Takeda, who is polite, plucky about everything, and a bit clueless about volleyball. I just think they have a great vibe as co-workers ...

Takeda has made some cuts to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising candidates. Let’s start in phase 2.

The restructuring plan was announced on the same day Takeda released its FY 2023 results. Image credit: Shutterstock/Tada Images. Takeda’s annual profits for FY 2023 have been hit by more than 50%, ...

Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday when the drugmaker axed (PDF) a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from ...